On the public citation graph
Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer
0 signed · 24 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/jcb.20690openalex-snapshot
Cell cycle control in breast cancer cells
inferredcites →https://doi.org/10.1016/s1470-2045(14)71159-3openalex-snapshot
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
inferredcites →https://doi.org/10.1056/nejmoa1505270openalex-snapshot
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
inferredcites →https://doi.org/10.1093/annonc/mdw139openalex-snapshot
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-0509openalex-snapshot
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
inferredcites →https://doi.org/10.1158/1535-7163.1427.3.11openalex-snapshot
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
inferredcites →https://doi.org/10.1159/000443515openalex-snapshot
ABC3 Consensus: Assessment by a German Group of Experts
inferredcites →https://doi.org/10.1186/bcr2419openalex-snapshot
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
inferredcites →https://doi.org/10.1200/jco.2015.33.15_suppl.571openalex-snapshot
Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged ≥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial.
inferredcites →https://doi.org/10.1200/jco.2015.33.15_suppl.572openalex-snapshot
The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/ HER2- metastatic breast cancer (MBC): Subanalysis from a randomized phase II study.
inferredcites →https://doi.org/10.1200/jco.2015.33.15_suppl.575openalex-snapshot
Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18.
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4765196openalex-extracted
Discovery and Preclinical Evaluations of Tqb3616, a Novel Cdk4-Biased Inhibitor
inferred← citeshttps://doi.org/10.1002/cbdv.202500424openalex-snapshot
Insights Into Anticancer Mechanisms of Schisandrin B: Isolation, Pharmacokinetics, and Preclinical Evidence
inferred← citeshttps://doi.org/10.1007/s00401-017-1671-4openalex-snapshot
Glioma: experimental models and reality
inferred← citeshttps://doi.org/10.1016/j.bmcl.2024.129769openalex-snapshot
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
inferred← citeshttps://doi.org/10.1016/j.bmcl.2024.129941openalex-snapshot
Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development
inferred← citeshttps://doi.org/10.1016/j.ebiom.2024.105177openalex-snapshot
Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.1038/s41467-019-10135-xopenalex-snapshot
Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
inferred← citeshttps://doi.org/10.1111/joim.12609openalex-snapshot
Understanding cell cycle and cell death regulation provides novel weapons against human diseases
inferred← citeshttps://doi.org/10.1155/2020/2172740openalex-snapshot
A Comprehensive Review on Schisandrin B and Its Biological Properties
inferred← citeshttps://doi.org/10.1159/000447479openalex-snapshot
The Role of CDK 4/6 Inhibitors in Breast Cancer Treatment
inferred← citeshttps://doi.org/10.1177/20420986231188845openalex-snapshot
Clinical relevance of potential self-medication drug interactions in antineoplastic and immune-modulating therapy among online pharmacy customers
inferred← citeshttps://doi.org/10.17650/1994-4098-2016-12-2-46-51openalex-snapshot
Evolution of systemic treatment for hormone-sensitive breast cancer: from sequential use of single agents to the upfront administration of drug combinations
inferred← citeshttps://doi.org/10.3389/fmolb.2023.1116398openalex-snapshot
Investigation on acquired palbociclib resistance by LC-MS based multi-omics analysis
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.